VI
CSTL icon

Versor Investments’s Castle Biosciences CSTL Stock Holding History

Versor Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,238
Closed -$227K – 766
2024
Q1 		$227K Sell
10,238
-3,905
-28% -$85K 0.05% 586
2023
Q4 		$305K Sell
14,143
-400
-3% -$7.04K 0.06% 512
2023
Q3 		$246K Buy
+14,543
New +$254K 0.05% 546
2023
Q1 		– Sell
-11,275
Closed -$265K – 738
2022
Q4 		$265K Buy
11,275
+2,258
+25% +$52.3K 0.02% 556
2022
Q3 		$235K Sell
9,017
-13,050
-59% -$366K 0.01% 685
2022
Q2 		$484K Buy
+22,067
New +$513K 0.02% 488
2021
Q4 		– Sell
-3,700
Closed -$246K – 556
2021
Q3 		$246K Buy
+3,700
New +$260K 0.01% 434

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Versor Investments's CSTL Position: Q2 2024 in Review

Versor Investments sold out of Castle Biosciences (CSTL) in Q2 2024, closing a stake of 10,238 shares — an estimated $227K sold.

Versor Investments first reported a position in CSTL in Q3 2021 and held it in 7 quarters. The position peaked at $484K in Q2 2022. 159 funds tracked by Wall St. Rank hold CSTL as of Q2 2024.

  • Versor Investments reported no remaining Castle Biosciences position as of Q2 2024 after selling out during the quarter.
  • Versor Investments sold 10,238 Castle Biosciences shares in Q2 2024, an estimated $227K.
  • Versor Investments first reported a position in Castle Biosciences in Q3 2021 and held it in 7 quarters.
  • Versor Investments's Castle Biosciences position peaked at $484K in Q2 2022.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2024.

Based on Versor Investments's 13F filing for Q2 2024, filed 1 Aug 2024.